Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PML Antibodies:
anti-Mouse (Murine) PML Antibodies:
anti-Rat (Rattus) PML Antibodies:
Go to our pre-filtered search.
Human Polyclonal PML Primary Antibody for ICC, IF - ABIN252967
Wimmer, Schreiner, Everett, Sirma, Groitl, Dobner: SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML. in Oncogene 2010
Show all 21 Pubmed References
Human Polyclonal PML Primary Antibody for IHC (p), ELISA - ABIN545269
Kawai, Akira, Reed: ZIP kinase triggers apoptosis from nuclear PML oncogenic domains. in Molecular and cellular biology 2003
Show all 3 Pubmed References
Human Polyclonal PML Primary Antibody for ICC, IF - ABIN4346484
Campagna, Herranz, Garcia, Marcos-Villar, González-Santamaría, Gallego, Gutierrez, Collado, Serrano, Esteban, Rivas: SIRT1 stabilizes PML promoting its sumoylation. in Cell death and differentiation 2010
Show all 3 Pubmed References
Human Polyclonal PML Primary Antibody for ICC, IF - ABIN252968
Kuroki, Ariumi, Ikeda, Dansako, Wakita, Kato: Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. in Journal of virology 2009
Show all 2 Pubmed References
Mouse (Murine) Monoclonal PML Primary Antibody for ICC, IF - ABIN2668256
Evdokimov, Sharma, Lockett, Lualdi, Kuehn: Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. in Journal of cell science 2008
Human Polyclonal PML Primary Antibody for ELISA, ICC - ABIN6264315
Wu, Shao, Zhou, Sun, Wang, Yan, Liu, Wu, Ye, Huang, Zhou et al.: Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo ... in Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018
Mouse (Murine) Polyclonal PML Primary Antibody for IHC, WB - ABIN3021659
Li, Zhong, Liu, Yu, Chen, Wang, Shi, Yuan: Evidence for Kaposi Sarcoma Originating from Mesenchymal Stem Cell through KSHV-induced Mesenchymal-to-Endothelial Transition. in Cancer research 2018
BRD4 and PML/RARalpha co-existed on the same regulatory regions of their target genes. Hence, the study showed a new discovery of the interaction of BRD4 and PML/RARalpha, as well as the decline of PML/RARalpha expression in NB4 cells, under JQ1 treatment.
As(3+) selectively reorganizes PML and SUMO2/3 monomers into insoluble forms in PML-NBs, and then PML SUMOylation proceeds.
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.
The cellular nuclear domain 10 (ND10) complex plays an important role in suppressing HHV-6A lytic replication and the silencing of the virus genome in latently infected cells.
Despite the rarity of acute promyelocytic leukemia (APL) cases with an atypical PML/RARA fusion, our study indicates that an integrated laboratory approach, employing several diagnostic techniques is crucial to timely diagnose APL. This approach allows prompt initiation of specific targeted treatment and reliable MRD monitoring in atypical APL cases.
Depletion of PML significantly impacts the chromatinization of the latent/quiescent HSV-1 viral genomes with histone H3.3 without any overall replacement with H3.1.
PML and RARA breakpoint translocation is associated with acute promyelocytic leukemia.
these findings uncover a novel mechanism by which PML loss may contribute to mTOR activation and cancer progression via dysregulation of basal DDIT4 gene expression.
This study establishes PML as an important regulator of NF-kappaB and demonstrates that PML-RARalpha dysregulates NF-kappaB.
STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region.
Respiratory syncytial virus induces NRF2 degradation through a PML-RNF4 pathway.
Data suggest that intracellular host defenses are counteracted by ICP0, which targets PML for degradation from the outset of nuclear infection to promote viral-DNA release from PML-nuclear bodies and the onset of HSV-1 lytic replication. (ICP0 = immediate early infected polypeptide-0; PML = promyelocytic leukemia protein; HSV-1 = herpes simplex virus-1)
the PML(NLS-) protein was detectable in the cytoplasm of neutrophils from patients with acute promyelocytic leukemia.
The PML sumo interaction motif differentially affects nuclear body formation by each individual isoform.
inhibiting CK2 can enhance sensitivity of Cisplatin to Non-small cell lung carcinoma cells through PML
Results show that PolySUMO5 conjugation on K160 of PML results in recruitment of proteins to form PML-nuclear bodies. SUMO5 conjugation on PML is gradually replaced by SUMO2/3 conjugation, which leads to RNF4-mediated disruption of PML-NBs.
the ND10 bodies become viral replication compartments, and ICP0, a viral E3 ligase, degrades both PML and SP100. The amounts of PML and SP100 and the number of ND10 structures increase in cells exposed to IFN-beta.
These results therefore indicate that EGCG targets PML/RARalpha oncoprotein for degradation and potentiates differentiation of promyelocytic leukemia cells in combination with ATRA via PTEN.
Mechanically, mutant NPM1 interacted with PML and mediated its delocalization as well as stabilization contributing to elevated autophagic activity and leukemic cell survival in vitro.
study revealed molecular mechanism of responsiveness of the PML-RARA mutations to AS2O3 treatment; mutation S214L disrupted PML-arsenic binding, nuclear body formation, basal SUMOylation and degradation; mutation A216T showed moderate defect in AS2O3 response;, mutants L217F and S220G behave similarly to wild-type; findings suggest distinct mutants of PML-RARA confer varying degree of AS2O3 resistance
Pml Nuclear bodies (NB) are critical for DNA damage responses, and Pml NB disruption is a central contributor to Acute promyelocytic leukemia pathogenesis.
PML mediates the binding of PER2 to BMAL1 in the BMAL1/CLOCK heterodimer and is an important component in the organization of a functional clock complex in the nucleus.
Promyelocytic leukemia protein Pml -/- cells showed a higher proliferation rate, compared to Pml +/+ cells.
PML protein organizes heterochromatin domains where it regulates histone H3.3 deposition by ATRX and DAXX.
Data indicate that promyelocytic leukemia protein knockout (Pml-/-) animals fail to properly activate oxidative stress-responsive p53 targets, whereas the NRF2 response is amplified and accelerated.
data support a model in which activation of myogenic differentiation results in PML NB loss, chromatin reorganization and DAXX relocalization, and provides a paradigm for understanding the consequence of PML loss in other cellular contexts, such as during cancer development and progression
a regulatory role of ZNF451-1 in fine-tuning physiological PML levels
PML loss promotes tumor development, providing a growth advantage to tumor cells that use autophagy as a cell survival strategy during stress conditions.
The data demonstrate a dual role of PML in protection and recovery after brain injury.
This study designates PML protein and PML-NBs to be major cellular components involved in the control of Herpes simplex virus 1 (HSV-1) latency, probably during the entire life of an individual.
Study found that Promyelocytic leukemia protein (PML) is broadly expressed across the gray matter, with the highest levels in the cerebral and cerebellar cortices. PML bodies are broadly involved in activity-dependent nuclear phenomena in adult neurons
These findings suggest that the UBC9/PML/RNF4 axis plays a critical role as an important SUMO pathway in cardiac fibrosis. Modulating the protein levels of the pathway provides an attractive therapeutic target for the treatment of cardiac fibrosis and heart failure.
PML contributes to the intrinsic restriction of HIV-1 infections in a cell type-dependent manner.
both the PML-RARA-driven competitive transplantation advantage and development of acute promyelocytic leukemia (APL) required DNMT3A
PML IV enhances global SUMO-1 conjugation, particularly that of p53, resulting in p53 stabilization and activation.
our findings challenge the predominant model in the field and we propose that PML/RARA initiates leukemia by subtly shifting cell fate decisions within the promyelocyte compartment.
DNA-binding-defective PML/RARA mutants could not repress the transcription of retinoic acid regulated genes.
A novel antioxidative mechanism by which PML regulates cellular oxidant homeostasis by controlling complex II integrity and Nrf2 activity and identified PML as an indispensable mediator of SFN activity.
pRB can interact with PML specifically during senescence, suggesting that signaling events in senescence regulate assembly of PML and pRB to establish heterochromatin and create a permanent cell cycle arrest.
Data suggest that acute promyelocytic leukemia (APL) differentiation is a default program triggered by clearance of promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein PML/RARA-bound promoters.
The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. This phosphoprotein localizes to nuclear bodies where it functions as a transcription factor and tumor suppressor. Its expression is cell-cycle related and it regulates the p53 response to oncogenic signals. The gene is often involved in the translocation with the retinoic acid receptor alpha gene associated with acute promyelocytic leukemia (APL). Extensive alternative splicing of this gene results in several variations of the protein's central and C-terminal regions\; all variants encode the same N-terminus. Alternatively spliced transcript variants encoding different isoforms have been identified.
RING finger protein 71
, probable transcription factor PML
, promyelocytic leukemia protein
, promyelocytic leukemia, inducer of
, protein PML
, tripartite motif protein TRIM19
, tripartite motif-containing protein 19
, promyelocytic leukemia
, probable transcription factor PML-like